LENZ Therapeutics Stock Quote LENZ - Stock Price, News, Charts, Message Board, Trades

Unlock more advanced trading tools

Join ADVFN today

Current Price

15.72

Bid

14.20

Ask

18.33

Volume

200,720

15.05 Day's Range 16.00

15.05 52 Week Range 24.59

Market Cap

910.537M

Previous Close

15.45

Open

15.36

Last Trade

15.59

Last Trade Time

Financial Volume

$ 3,135,991

VWAP

15.6237

Average Volume (3m)

115,062

Shares Outstanding

57,996,000

Dividend Yield

PE Ratio

-7.30

Earnings Per Share (EPS)

-2.15

Revenue

Net Profit

-124.65M

Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert ... Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its lead product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States. Show more

Sector

Biological Pds,ex Diagnstics

Industry

Biological Pds,ex Diagnstics

Website

www.lenz-tx.com

Headquarters

Wilmington, Delaware, USA

Founded

1970

LENZ Therapeutics Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker LENZ. The last closing price for LENZ Therapeutics was $15.45. Over the last year, LENZ Therapeutics shares have traded in a share price range of $ 15.05 to $ 24.59.

LENZ Therapeutics currently has 57,996,000 shares outstanding. The market capitalization of LENZ Therapeutics is $910.54 million. LENZ Therapeutics has a price to earnings ratio (PE ratio) of -7.30.

LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials

– LNZ100 selected as lead candidate – Primary endpoint was met with 71% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours – Rapid onset and long duration...

LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials

Conference call and webcast on Wednesday, April 3, 2024, at 8:00 a.m. EST LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-1.68	-9.65517241379	17.4	17.66	15.05	122934	15.78444978	CS
4	-6.5	-29.2529252925	22.22	24.59	15.05	101189	19.00288813	CS
12	-0.26	-1.62703379224	15.98	24.59	15.05	115062	19.20985291	CS
26	-0.26	-1.62703379224	15.98	24.59	15.05	115062	19.20985291	CS
52	-0.26	-1.62703379224	15.98	24.59	15.05	115062	19.20985291	CS
156	-0.26	-1.62703379224	15.98	24.59	15.05	115062	19.20985291	CS
260	-0.26	-1.62703379224	15.98	24.59	15.05	115062	19.20985291	CS

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
BDRXBiodexa Pharmaceuticals PLC	$ 1.3254 (82.86%)	70.82M
IBRXImmunityBio Inc	$ 7.35 (43.84%)	40.28M
AGENAgenus Inc	$ 11.685 (40.78%)	3.37M
ULHUniversal Logistics Holdings Inc	$ 45.63 (38.74%)	484.22k
NIVFNewGenIvf Group Ltd	$ 1.77 (36.15%)	57.78M
MFImF International Ltd	$ 2.3153 (-77.82%)	21.23M
NWGLNature Wood Group Ltd	$ 5.05 (-70.03%)	2.48M
ICLKiClick Interactive Asia Group Ltd	$ 1.21 (-52.17%)	719.95k
NUWENewellis Inc	$ 0.1695 (-41.35%)	18.46M
SGBXSafe and Green Holdings Corporation	$ 0.1469 (-32.92%)	8.39M
PEGYPineapple Energy Inc	$ 0.065499 (26.20%)	325.57M
SQQQProShares UltraPro Short QQQ	$ 11.43 (-4.75%)	137.28M
INTCIntel Corporation	$ 31.88 (-9.20%)	119.84M
TSLATesla Inc	$ 168.29 (-1.11%)	109.84M
SOFISoFi Technologies Inc	$ 7.87 (3.69%)	88.63M